Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 22c
May 9, 2016 7:46 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.06), $0.22 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $17.33 million.
Cash and cash equivalents were $78.3 million as of March 31, 2016.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More